Neurology

Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025
Annovis Bio Inc. will present significant advancements in Alzheimer’s treatment at the Alzheimer’s Association International Conference 2025, highlighting the potential of its lead candidate, buntanetap.

NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug PrimeC
NeuroSense Therapeutics' progress with Health Canada for its ALS drug PrimeC could accelerate approval and bolster a significant pharmaceutical partnership, highlighting a pivotal moment for ALS treatment and the biotech sector.

New Scanning Method Research Funded to Improve Brain Tumor Treatment
Researchers from NHS Grampian and the University of Aberdeen receive funding to explore a novel scanning method that could enhance the treatment of aggressive brain tumors, specifically glioblastomas.

Lexaria Bioscience Corp. Achieves Global Patent Milestone with 50 Patents
Lexaria Bioscience Corp. has reached a significant milestone with 50 patents granted worldwide, including new patents for epilepsy treatment and sublingual nicotine delivery, marking a pivotal moment in the company's strategy to expand its drug delivery platform.

Quantum BioPharma Ltd. Advances in Brain and Alcohol Health Research with Phase 2 Trial Approval
Quantum BioPharma Ltd. makes significant strides in its brain disorders and alcohol health pipeline, including Phase 2 trial approval for FSD202 and preparations for an IND filing for Lucid-MS, highlighting its commitment to addressing unmet medical needs.

Cure Alzheimer’s Fund Honors Breakthrough Research with Jeffrey L. Morby Prize
The Cure Alzheimer’s Fund has awarded the Jeffrey L. Morby Prize to researchers Andrew S. Yoo and Zhao Sun for their innovative study on modeling late-onset Alzheimer’s disease, marking a significant step forward in understanding and potentially treating the condition.

Quantum BioPharma Advances MS Research with Groundbreaking PET Imaging Study
Quantum BioPharma Ltd. has initiated a pioneering PET imaging study with Massachusetts General Hospital to track myelin integrity in multiple sclerosis patients, potentially revolutionizing treatment evaluation.

Study Reveals Accelerated Biological Aging in Children with Multiple Sclerosis
New research from UC San Diego indicates that children and adolescents with multiple sclerosis experience faster biological aging, highlighting the urgent need for targeted therapies.

Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events
Oragenics Inc. (NYSE American: OGEN) is set to present its intranasal neurosteroid candidate for concussion treatment, ONP-002, at two significant 2025 events, highlighting its potential impact on neurology and pharmaceutical sectors.

Neuroscientists Develop RADICAL: A Breakthrough Tool for Precise Neural Control
Researchers have engineered a novel chemogenetic tool called RADICAL that enables non-invasive, precise manipulation of brain activity using a synthetic chemical, offering significant potential for neuroscience research and therapeutic interventions.

Swedish Study Reveals Potential Neurological Connection Between Autism and Parkinson's Disease
A groundbreaking research from Karolinska Institutet suggests a significant biological link between autism spectrum disorder and Parkinson's disease, potentially opening new avenues for understanding neurodegenerative conditions.

Alzamend Neuro Advances Innovative Therapies for Mental Health Disorders
Alzamend Neuro is developing novel therapeutic approaches for challenging neurological and psychiatric conditions, including Alzheimer's, Bipolar Disorder, Major Depressive Disorder, and PTSD. The company's pioneering treatments aim to improve patient outcomes by addressing current treatment limitations.

Alzamend Neuro Launches Phase II Trial for Innovative Lithium-Based Alzheimer's Therapy
Alzamend Neuro has initiated a Phase II clinical trial for AL001, a novel lithium therapy targeting multiple neuropsychiatric conditions, with potential to improve brain drug delivery and reduce side effects.

Breakthrough Brain Tumor Test Promises Faster Diagnosis
A new diagnostic test for brain tumors could dramatically reduce the time needed for accurate diagnosis, potentially improving patient outcomes by enabling quicker treatment decisions.

New Research Illuminates Potential Link Between Epstein-Barr Virus and Multiple Sclerosis
Scientific research is uncovering a complex relationship between Epstein-Barr virus exposure and Multiple Sclerosis, highlighting the potential for deeper understanding of disease mechanisms and future treatment strategies.

Viral TikTok Video Highlights Simple Hand Motion Test for Potential Brain Tumor Detection
A social media trend reveals a 30-second hand test that could help individuals identify potential undiagnosed brain health issues, raising awareness about early symptom recognition.

Oragenics Receives Australian Approval for Phase II Concussion Trial
Biotechnology company Oragenics has secured regulatory approval to launch a Phase II clinical trial for ONP-002, a novel intranasal therapy targeting mild traumatic brain injury. The trial represents a potential advancement in treating concussions with a non-invasive approach.

CNS Pharmaceuticals Secures Orphan Drug Designation for Brain Cancer Treatment
CNS Pharmaceuticals has transferred Orphan Drug Designation for TPI 287, a promising microtubule-stabilizing drug targeting brain cancer and neurological conditions. The designation could provide significant market advantages and potential treatment options for patients with challenging neurological disorders.

Oragenics to Discuss Promising Concussion Treatment in Upcoming Webinar
Biotechnology company Oragenics will host a management webinar to highlight its lead intranasal therapy ONP-002, currently in Phase IIa trials for mild traumatic brain injury, potentially addressing an unmet medical need in concussion treatment.

Simple Eye Exam Could Enable Early Parkinson's Detection, Researchers Find
A new study from Universite Laval suggests that a straightforward retinal examination might provide an early diagnostic method for Parkinson's disease, potentially transforming how medical professionals identify and track the neurological condition.

Clene Inc. Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
Clene Inc. reports promising progress on its CNM-Au8 therapy for ALS, with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway, supported by significant survival data and reduced expenses.

Clene Inc. Advances Promising Therapy for ALS, Targets Accelerated FDA Approval
Clene Inc. reports significant progress on CNM-Au8, a potential breakthrough therapy for amyotrophic lateral sclerosis (ALS), with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway in Q4 2025. New data demonstrates improved patient survival and neurological repair.

Holistic Healing Practitioner Expands Expertise with Advanced Brain and Lymphatic Therapy Training
Carol McCoon, a holistic healing practitioner, is advancing her professional skills through specialized training in Brain Therapy and Lymph Drainage Therapy, offering personalized healing techniques that address neurological and lymphatic dysfunctions.

Telomir Pharmaceuticals Advances Neurological Research with Novel Cellular Restoration Candidate
Telomir Pharmaceuticals reveals promising preclinical data for Telomir-1, a small molecule targeting cellular decline, with potential applications in autism spectrum disorder and rare neurological conditions. The research demonstrates potential breakthrough in understanding age-related cellular deterioration.

Clene Inc. to Present at D. Boral Capital Global Conference in New York
Clene Inc., a late clinical-stage biopharmaceutical company developing neurological disease treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors an opportunity to learn about its innovative research and potential therapeutics.

Annovis Bio Bolsters Neurodegenerative Research with Key Biostatistics Appointment
Annovis Bio strengthens its scientific team by appointing Hui Liu as Director of Biostatistics, enhancing its capabilities in clinical trial design and data analysis for neurodegenerative disease research.

New Research Links Specific Bacteria to Multiple Sclerosis Risk
A twin-based study reveals that certain bacterial compositions may significantly influence multiple sclerosis development, potentially offering new insights into disease prevention and treatment strategies.

Dr. Nupur Ghoshal Receives Alois Alzheimer Award for Groundbreaking Dementia Research
Dr. Nupur Ghoshal, a distinguished neurologist and researcher at Washington University School of Medicine, has been honored with the prestigious Alois Alzheimer Award for her significant contributions to understanding and advancing Alzheimer's and dementia research.

Common Migraine Drug Shows Promise in Reducing Stroke Risk for Women
New research reveals propranolol, a widely-used medication for migraines and high blood pressure, may significantly reduce ischemic stroke risk in women with migraines, particularly those without aura, highlighting an important advancement in women's cardiovascular health management.

Mediterranean Diet Linked to Enhanced Brain Health in Hispanic Adults, Study Shows
A new study reveals significant brain health benefits for Hispanic/Latino adults following a Mediterranean diet, with improvements in brain connectivity and structure independent of cardiovascular factors, highlighting important implications for the fastest-growing ethnic group in the U.S.